Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04965675 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine

Study acronym: PROSPECT-2
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated August 21, 2026 (before its estimated September 5, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study sites: 84 to 83v44
  2. Site details revised at 3 of 84 sitesv43
  3. Site details revised at 10 of 84 sitesv42
  4. Study sites revised (84)v41 See this version in full on ClinicalTrials.gov ↗
  5. Site details revised at 1 of 84 sitesv40
Show 38 earlier versionsHide 38 earlier versions
  1. Study sites: 83 to 84v39
  2. Site details revised at 1 of 83 sitesv38
  3. Study sites revised (83)v37 See this version in full on ClinicalTrials.gov ↗
  4. Study sites: 82 to 83v36
  5. Primary completion date: Feb 3, 2026 to Sep 5, 2026 Completion date: Mar 31, 2026 to Oct 31, 2026 · Study sites revised (82)v35 Show 2 more changesShow less
    • Completion date: Mar 31, 2026 to Oct 31, 2026
    • Study sites revised (82)

    See this version in full on ClinicalTrials.gov ↗

  6. Study sites: 81 to 82v34
  7. Study sites: 76 to 81v33
  8. Study sites: 75 to 76v32
  9. Study sites revised (75)v31 See this version in full on ClinicalTrials.gov ↗
  10. Study sites: 73 to 75v30
  11. Primary completion date: Oct 31, 2024 to Feb 3, 2026 Study sites: 72 to 73 · Completion date: Oct 31, 2024 to Mar 31, 2026v29 Show 2 more changesShow less
    • Study sites: 72 to 73
    • Completion date: Oct 31, 2024 to Mar 31, 2026
  12. Site details revised at 3 of 72 sitesv28
  13. Study sites: 71 to 72v27
  14. Site details revised at 1 of 71 sitesv26
  15. Study sites: 69 to 71v25
  16. Study sites: 65 to 69v24
  17. Study sites: 64 to 65v23
  18. Study sites: 63 to 64v22
  19. Study sites: 61 to 63v21
  20. Primary completion date: Dec 3, 2023 to Oct 31, 2024 Study sites: 58 to 61 · Completion date: Jan 28, 2024 to Oct 31, 2024v20 Show 2 more changesShow less
    • Study sites: 58 to 61
    • Completion date: Jan 28, 2024 to Oct 31, 2024
  21. Study sites: 57 to 58v19
  22. Study sites: 36 to 57 Eligibility criteria expanded, about 4 wordsv18 Show 1 more changeShow less
    • Eligibility criteria expanded, about 4 words

    See this version in full on ClinicalTrials.gov ↗

  23. Study sites: 35 to 36v17
  24. Study sites: 34 to 35v16
  25. Study sites: 30 to 34v15
  26. Study sites: 28 to 30v14
  27. Study sites: 24 to 28v13
  28. Study sites: 21 to 24v12
  29. Study sites: 16 to 21v11
  30. Study sites: 13 to 16v10
  31. Study sites: 8 to 13v9
  32. Study sites: 6 to 8v8
  33. Study sites: 5 to 6v7
  34. Study sites: 4 to 5v6
  35. Study sites: 3 to 4v5
  36. Study sites: 2 to 3v4
  37. Study sites: 1 to 2v3
  38. Primary completion date: Oct 1, 2024 to Dec 3, 2023 Completion date: Oct 10, 2024 to Jan 28, 2024v2 Show 1 more changeShow less
    • Completion date: Oct 10, 2024 to Jan 28, 2024
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
H. Lundbeck A/S
20 trials monitored
See 1 trial at risk
Migraine
467 trials monitored
See 24 trials at risk
To find out if eptinezumab is better than placebo (normal saline solution) in lowering the number of days with migraine in young people ages 12 to 17 with chronic migraine.
Trial Details
NCT Number NCT04965675
Lead Sponsor H. Lundbeck A/S
Conditions Chronic Migraine in Children
Enrollment 285 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov